Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

Myriad Genetics, Inc. (MYGN)

Today's Latest Price: $11.58 USD

0.33 (2.93%)

Updated Jul 2 4:00pm

Add MYGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

MYGN Stock Summary

  • With a one year PEG ratio of 0.84, Myriad Genetics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 19.62% of US stocks.
  • Over the past twelve months, MYGN has reported earnings growth of -680.94%, putting it ahead of only 2.84% of US stocks in our set.
  • In terms of volatility of its share price, MYGN is more volatile than 79.98% of stocks we're observing.
  • Stocks that are quantitatively similar to MYGN, based on their financial statements, market capitalization, and price volatility, are HBIO, KVHI, DSS, CCUR, and DHX.
  • MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to
MYGN Daily Price Range
MYGN 52-Week Price Range

MYGN Stock Price Chart Technical Analysis Charts

MYGN Price/Volume Stats

Current price $11.58 52-week high $48.40
Prev. close $11.25 52-week low $9.24
Day low $11.41 Volume 1,213,984
Day high $11.97 Avg. volume 1,185,895
50-day MA $14.01 Dividend yield N/A
200-day MA $21.23 Market Cap 863.35M

Myriad Genetics, Inc. (MYGN) Company Bio

Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.

MYGN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MYGN Latest Social Stream

Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics Unveils New Home DNA Sample Collection Kit

Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.

Yahoo | July 2, 2020

Myriad Genetics launches GeneSight home collection kit

Myriad Genetics (MYGN) announces the launch of a new patient home collection kit for its GeneSight Psychotropic test.Patient DNA for the assay is collected with a cheek swab. Afterward, the patient puts the swab in a prepaid pre-addressed shipping envelope for transport back to Myriad for testing....

Seeking Alpha | July 1, 2020

Myriad Launches New GeneSight® Psychotropic Patient Collection Kit

Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home collection kit for the GeneSight® Psychotropic test. The kit allows the DNA sample collection typically administered in a clinician’s office to be completed at home. The new direct-to-patient collection kit must still be ordered by a licensed healthcare provider.

Yahoo | July 1, 2020

Myriad Genetics' myPath Melanoma Proved Superior Per New Study

Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.

Yahoo | June 29, 2020

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today that a new study published in Future Medicine demonstrates the ability of myPath® Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review. “This validation study for myPath Melanoma demonstrates the ability of the test to accurately classify lesions which are ruled indeterminate by an expert dermatopathologist,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Importantly, this accuracy was linked to the gold standard endpoint of real world clinical outcomes demonstrating the accuracy of the myPath Melanoma test result for patients and physicians concerned about this deadly cancer.”

Yahoo | June 25, 2020

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo -25.29%
3-mo -5.39%
6-mo -56.87%
1-year -58.60%
3-year -54.98%
5-year -66.50%
YTD -57.47%
2019 -6.33%
2018 -15.36%
2017 106.03%
2016 -61.38%
2015 26.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9495 seconds.